Jennifer Rosenthal
Corporate Officer/Principal chez VIRALYTICS LTD.
Postes actifs de Jennifer Rosenthal
Sociétés | Poste | Début | Fin |
---|---|---|---|
VIRALYTICS LTD. | Corporate Officer/Principal | - | - |
CLARITY PHARMACEUTICALS LTD | Conseiller Juridique Général | 01/10/2019 | - |
Historique de carrière de Jennifer Rosenthal
Anciens postes connus de Jennifer Rosenthal
Sociétés | Poste | Début | Fin |
---|---|---|---|
THE SUSTAINABLE NUTRITION GROUP LTD | Directeur Technique/Scientifique/R&D | 01/01/2006 | - |
Formation de Jennifer Rosenthal
Monash University | Doctorate Degree |
Statistiques
Internationale
Australie | 5 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 3 |
Process Industries | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
CLARITY PHARMACEUTICALS LTD | Health Technology |
Entreprise privées | 2 |
---|---|
The Sustainable Nutrition Group Pty Ltd.
The Sustainable Nutrition Group Pty Ltd. Agricultural Commodities/MillingProcess Industries The Sustainable Nutrition Group Ltd. produces, manufactures, and distributes a range of hemp products in Australia. It is involved in hemp seed selection, farming, processing, and packaging, as well as distribution and sale of bulk and retail products. The company's products include hand sanitizers, hemp oils, hemp seeds, hemp protein powders, and hemp flour under the APH and Mt Elephant brands to retail, wholesale, and white label customers. The company was founded by James Hood and Tracie Rams dale in 1995 and is headquartered in Newtown, Australia. | Process Industries |
Viralytics Pty Ltd.
Viralytics Pty Ltd. BiotechnologyHealth Technology Viralytics Pty Ltd. engages in the development and commercialization of oncolytic immunotherapies that harness the power of certain viruses to infect and kill cancer cells. Its product, CAVATAK, is a genetically unmodified proprietary formulation of the common cold Coxsackievirus Type A21. The company was founded in 1984 and is headquartered in Sydney, Australia. | Health Technology |
- Bourse
- Insiders
- Jennifer Rosenthal
- Expérience